[1]
R. B. Silva, “Empaglifozin cardiovascular benefit: can we separate fact from fiction?”,
Evidence
, vol. 1, no. 1, pp. 43–45, Jun. 2019,
doi: 10.17267/2675-021Xevidence.v1i1.2095.